Enliven Therapeutics

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP EPS of -$0.49 vs. -$0.39 expected. As a clinical-stage biopharmaceutical company, revenue remained at $0.0, in-line with expectations. The net loss widened to $32.5M compared to the $26.5M expected, primarily driven by a surge in R&D internal expenses including $9.4M in stock-based compensation. Despite the earnings miss, the company strengthened its liquidity significantly through a $460M public offering in June 2026, ending the quarter with $895.2M in cash and marketable securities.